GlassScriptPhysician profile
Jason Jude Bayard
NPI 1184034886
$6,326.38
in general payments reported to CMS, 2019-2025
26 companies · $2,371 in 2025
The $2,371 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $943 · 2022: $949 · 2023: $829 · 2024: $1,234 · 2025: $2,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,418 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,417.58 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,662.18 | 2021-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,498.25 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $713.76 | 2021-2025 | Dupixent |
| Genzyme Corporation | $476.11 | 2021-2025 | |
| Insmed, INC. | $261.95 | 2021-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $257.95 | 2021-2024 | Yupelri |
| Verona Pharma, INC. | $228.02 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $145.40 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $134.68 | 2021-2023 | |
| Amgen INC. | $124.20 | 2022-2024 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.47 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $100.32 | 2021-2025 | Winrevair, Keytruda |
| Ani Pharmaceuticals, INC. | $96.93 | 2024-2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $91.42 | 2022-2023 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $86.65 | 2021-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $63.52 | 2021-2025 | Acthar |
| Inspire Medical Systems, INC. | $45.45 | 2025 | Inspire |
| Grifols USA, LLC | $37.42 | 2021 | |
| United Therapeutics Corporation | $32.68 | 2025 | Tyvaso |
| Philips North America LLC | $28.05 | 2025 | Lm Undivided |
| Axsome Therapeutics, INC. | $26.59 | 2023 | Sunosi |
| Baxter Healthcare | $21.52 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Novartis Pharmaceuticals Corporation | $21.50 | 2022 | |
| Liquidia Technologies, INC. | $18.97 | 2025 | Yutrepia |
| Lilly USA, LLC | $17.69 | 2025 | Zepbound |
| Gilead Sciences, INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Bayard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.